Home  /  Resource Library  /  Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naive Chronic Lymphocytic Leukemia

Long-Term Follow up of Front-Line Therapy with Ofatumumab, High Dose Methylprednisolone and Lenalidomide (HiLO trial) for Treatment-Naive Chronic Lymphocytic Leukemia

Results of a phase II study investigating the combination of Ofatumumab, High Dose Methylprednisolone and Lenalidomide for first line treatment of CLL.